Disclaimer

The information on this website is presented as a service for our clients and Internet users and is not intended to be legal advice, nor should you consider it as such. Although we welcome your inquiries, please keep in mind that merely contacting us will not establish an attorney-client relationship between us. Consequently, you should not convey any confidential information to us until a formal attorney-client relationship has been established. Please remember that electronic correspondence on the internet is not secure and that you should not include sensitive or confidential information in messages. With that in mind, we look forward to hearing from you.

 Skip to Content

Carlton Fields IP Attorneys Author Article for Law360: Amgen, Juno And The Fate Of Functional Genus Claims
June 08, 2022

Four Carlton Fields attorneys — J. Coy Stull, Katherine Teal Leonard, Ahmed-Zayn Mohamed, and Meredith Little — authored an article, “Amgen, Juno and the Fate of Functional Genus Claims,” for Law360. The article discusses the evidence offered and rejected by the Federal Circuit in Juno Therapeutics, Inc. v. Kite Pharma and Amgen v. Sanofi, and by the District Court (by a Federal Circuit Judge presiding) in Baxalta Inc. v. Genentech, Inc. It also discusses the possible ramifications of potential Supreme Court intervention in Amgen v. Sanofi (cert petition pending) and Juno v. Kite (cert petition expected in mid-June).

READ the article.
Featuring
Image: J. Coy Stull
J. Coy Stull
Image: Ahmed-Zayn Mohamed
Ahmed-Zayn Mohamed
Related Practices
Intellectual Property